Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist

Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain

Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the WCIRD23 Annual Meeting.

InSphero Partners with ALPCO to Advance Diabetes Research Schlieren, Switzerland, June 11, 2018 (GLOBE NEWSWIRE) -- InSphero AG, the leading provider of 3D cell-based platforms for preclinical drug safety and efficacy testing, today announced that it is...